TP53 and non-small cell lung carcinoma: These results from the cell model and human tissues support the hypothesis that a decrease in miR-184 by E6 oncoprotein may play more important role than p53 mutation status on the elevation of Bcl-2 expression and consequently to confer cisplatin resistance and unfavorable response to cisplatin-based chemotherapy in NSCLC.